FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Highlighting the promising role of Thymosin alpha 1 in treating severe acute pancreatitis by modulating immune responses and reducing complications.
返回研究图书馆
Thymosin alpha 1Tα1

Highlighting the promising role of Thymosin alpha 1 in treating severe acute pancreatitis by modulating immune responses and reducing complications.

May 16, 2026
Share

原始论文

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

Tian Yong et al.Frontiers in immunology2025
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文将上述源论文的研究成果分解成肽类研究社区易于理解的语言。我们的目标是突出最值得关注的内容 — 实用意义、证据强度以及对正在进行的研究的影响。

Thymosin Alpha 1 Shows Promise in Treating Severe Acute Pancreatitis

Published: May 16, 2026 | Source: Frontiers in immunology (2025) | Category: Thymosin alpha 1, Tα1

Overview

A recent systematic review and meta-analysis published in Frontiers in Immunology suggests that thymosin alpha 1 (Tα1), a peptide with known immune-modulating properties, may help alleviate inflammation and prevent infections in patients suffering from severe acute pancreatitis (SAP). This finding could pave the way for new therapeutic approaches using peptides to manage this life-threatening condition.

Study Background

Severe acute pancreatitis is characterized by intense inflammation of the pancreas that can lead to systemic complications such as multi-organ failure. Immune dysregulation plays a significant role in exacerbating these conditions, making immune modulation an attractive target for therapy. Thymosin alpha 1 (Tα1) has been used clinically for its ability to enhance immune responses and regulate the balance of immune cells. However, evidence supporting its efficacy specifically in SAP patients was limited prior to this study.

What the Research Found

The meta-analysis included five randomized controlled trials involving a total of 706 SAP patients. The studies evaluated the effects of Tα1 on various clinical outcomes, including immune cell profiles and infection rates. Key findings include:

  • Immune Cell Regulation: Tα1 administration led to an increase in CD4+ T-cell percentages, indicating its ability to modulate immune responses.
  • Infection Prevention: Patients treated with Tα1 had a lower incidence of infections compared to those who did not receive the peptide.
  • Reduced Inflammation: There was evidence that Tα1 helped alleviate inflammation associated with SAP.

What This Means for Peptide Users

While more research is needed, these findings suggest that thymosin alpha 1 could be a valuable addition to current treatment protocols for severe acute pancreatitis. For patients and healthcare providers considering peptide therapies, this study highlights the potential benefits of Tα1 in managing immune dysregulation and reducing complications associated with SAP.

Limitations and Caveats

The meta-analysis is based on data from only five randomized controlled trials, which limits its generalizability to a broader patient population. Additionally, heterogeneity among studies may affect the reliability of the results. Therefore, while promising, these findings should be interpreted cautiously until further research confirms the efficacy and safety of Tα1 in larger and more diverse populations.

How This Compares to Previous Research

Previous studies have explored the immune-modulating effects of thymosin alpha 1 but often with conflicting outcomes due to variations in study design and patient characteristics. This meta-analysis provides a comprehensive evaluation, offering clearer insights into the potential benefits of Tα1 for SAP patients compared to earlier literature.

Our Analysis

PeptideVault's analysis suggests that this systematic review and meta-analysis is well-conducted and adds valuable information to the existing body of research on thymosin alpha 1. The findings are promising but should be interpreted with caution due to the limited number of studies included and potential heterogeneity among them.

Key Takeaways

  • Immune Modulation: Tα1 shows promise in regulating immune cells, particularly CD4+ T-cells.
  • Infection Prevention: There is evidence that Tα1 can reduce infection rates in SAP patients.
  • Further Research Needed: Larger and more diverse clinical trials are required to confirm these findings.

Original Source

Citation: Tian Yong, Yao Jiaqi, Ma Yihan et al. (2025). Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.. Frontiers in immunology. DOI: 10.3389/fimmu.2025.1571456

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队准备。鼓励读者查阅 完整源论文 以获取完整方法和数据。 原始出版物可在 PubMed.

相关研究

Comments

Sign in to join the discussion

此分析基于同行评审研究仅用于教育目的。并不构成医疗建议。在使用任何肽类疗法之前,请咨询合格的医疗服务提供者。